ANNAPOLIS, Md., Sept. 3, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 10:25 a.m. EDT in Room 7.03, 7th Floor of the Millennium Broadway Hotel, New York.
Event: | Rodman & Renshaw Annual Global Investment Conference |
Date: | Monday, September 9, 2013 |
Place: | Millennium Broadway Hotel, New York, NY |
Time: | 10:25 am EDT |
About PharmAthene
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical threats. PharmAthene’s current biodefense portfolio includes the following product candidates:
- SparVax® - a next generation recombinant protective antigen (rPA) anthrax vaccine
- Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity associated with exposure to chemical nerve agents
- Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
In addition, in May 2013, the Delaware Supreme Court issued its ruling on the appeal in our litigation with SIGA Technologies, affirming the Court of Chancery’s finding that SIGA was liable for breach of contract, reversing its finding of promissory estoppel, and remanding the case back to the Court of Chancery to reconsider the appropriate remedy and award of attorney’s fees and expert witness costs in light of the Supreme Court’s opinion. For more information about PharmAthene, please visit www.PharmAthene.com.
SOURCE PharmAthene, Inc.
Help employers find you! Check out all the jobs and post your resume.
